A citation-based method for searching scientific literature

Curtis R Warren, Chad A Cowan. Trends Cell Biol 2018
Times Cited: 15







List of co-cited articles
85 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.
Paul W Burridge, Yong Fuga Li, Elena Matsa, Haodi Wu, Sang-Ging Ong, Arun Sharma, Alexandra Holmström, Alex C Chang, Michael J Coronado, Antje D Ebert,[...]. Nat Med 2016
415
33

Induction of pluripotent stem cells from adult human fibroblasts by defined factors.
Kazutoshi Takahashi, Koji Tanabe, Mari Ohnuki, Megumi Narita, Tomoko Ichisaka, Kiichiro Tomoda, Shinya Yamanaka. Cell 2007
33

iPSCORE: A Resource of 222 iPSC Lines Enabling Functional Characterization of Genetic Variation across a Variety of Cell Types.
Athanasia D Panopoulos, Matteo D'Antonio, Paola Benaglio, Roy Williams, Sherin I Hashem, Bernhard M Schuldt, Christopher DeBoever, Angelo D Arias, Melvin Garcia, Bradley C Nelson,[...]. Stem Cell Reports 2017
75
26

Common genetic variation drives molecular heterogeneity in human iPSCs.
Helena Kilpinen, Angela Goncalves, Andreas Leha, Vackar Afzal, Kaur Alasoo, Sofie Ashford, Sendu Bala, Dalila Bensaddek, Francesco Paolo Casale, Oliver J Culley,[...]. Nature 2017
273
26

Induced Pluripotent Stem Cell Differentiation Enables Functional Validation of GWAS Variants in Metabolic Disease.
Curtis R Warren, John F O'Sullivan, Max Friesen, Caroline E Becker, Xiaoling Zhang, Poching Liu, Yoshiyuki Wakabayashi, Jordan E Morningstar, Xu Shi, Jihoon Choi,[...]. Cell Stem Cell 2017
86
26

Large-Scale Profiling Reveals the Influence of Genetic Variation on Gene Expression in Human Induced Pluripotent Stem Cells.
Christopher DeBoever, He Li, David Jakubosky, Paola Benaglio, Joaquin Reyna, Katrina M Olson, Hui Huang, William Biggs, Efren Sandoval, Matteo D'Antonio,[...]. Cell Stem Cell 2017
93
26

Analysis of Transcriptional Variability in a Large Human iPSC Library Reveals Genetic and Non-genetic Determinants of Heterogeneity.
Ivan Carcamo-Orive, Gabriel E Hoffman, Paige Cundiff, Noam D Beckmann, Sunita L D'Souza, Joshua W Knowles, Achchhe Patel, Dimitri Papatsenko, Fahim Abbasi, Gerald M Reaven,[...]. Cell Stem Cell 2017
150
26

Induced pluripotent stem cell technology: a decade of progress.
Yanhong Shi, Haruhisa Inoue, Joseph C Wu, Shinya Yamanaka. Nat Rev Drug Discov 2017
658
26


Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform.
Chris Denning, Viola Borgdorff, James Crutchley, Karl S A Firth, Vinoj George, Spandan Kalra, Alexander Kondrashov, Minh Duc Hoang, Diogo Mosqueira, Asha Patel,[...]. Biochim Biophys Acta 2016
182
20


Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro.
Elena Matsa, Paul W Burridge, Kun-Hsing Yu, John H Ahrens, Vittavat Termglinchan, Haodi Wu, Chun Liu, Praveen Shukla, Nazish Sayed, Jared M Churko,[...]. Cell Stem Cell 2016
97
20

An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility.
Clay W Scott, Xiaoyu Zhang, Najah Abi-Gerges, Sarah D Lamore, Yama A Abassi, Matthew F Peters. Toxicol Sci 2014
69
20

Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells.
Scott D Lundy, Wei-Zhong Zhu, Michael Regnier, Michael A Laflamme. Stem Cells Dev 2013
453
20

Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity.
Oksana Sirenko, Evan F Cromwell, Carole Crittenden, Jessica A Wignall, Fred A Wright, Ivan Rusyn. Toxicol Appl Pharmacol 2013
90
20

Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies.
Gang Wang, Megan L McCain, Luhan Yang, Aibin He, Francesco Silvio Pasqualini, Ashutosh Agarwal, Hongyan Yuan, Dawei Jiang, Donghui Zhang, Lior Zangi,[...]. Nat Med 2014
549
20

Large, Diverse Population Cohorts of hiPSCs and Derived Hepatocyte-like Cells Reveal Functional Genetic Variation at Blood Lipid-Associated Loci.
Evanthia E Pashos, YoSon Park, Xiao Wang, Avanthi Raghavan, Wenli Yang, Deepti Abbey, Derek T Peters, Juan Arbelaez, Mayda Hernandez, Nicolas Kuperwasser,[...]. Cell Stem Cell 2017
95
20

The NextGen Genetic Association Studies Consortium: A Foray into In Vitro Population Genetics.
Curtis R Warren, Cashell E Jaquish, Chad A Cowan. Cell Stem Cell 2017
22
20

Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells.
Francesca Stillitano, Jens Hansen, Chi-Wing Kong, Ioannis Karakikes, Christian Funck-Brentano, Lin Geng, Stuart Scott, Stephan Reynier, Ma Wu, Yannick Valogne,[...]. Elife 2017
54
13

The price of innovation: new estimates of drug development costs.
Joseph A DiMasi, Ronald W Hansen, Henry G Grabowski. J Health Econ 2003
13

Growth of engineered human myocardium with mechanical loading and vascular coculture.
Nathaniel L Tulloch, Veronica Muskheli, Maria V Razumova, F Steven Korte, Michael Regnier, Kip D Hauch, Lil Pabon, Hans Reinecke, Charles E Murry. Circ Res 2011
434
13

Innovation in the pharmaceutical industry: New estimates of R&D costs.
Joseph A DiMasi, Henry G Grabowski, Ronald W Hansen. J Health Econ 2016
13

Incidence and contributors to potential drug-drug interactions in hospitalized patients.
Leanne Reimche, Alan J Forster, Carl van Walraven. J Clin Pharmacol 2011
35
13

Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging.
Graham T Dempsey, Khuram W Chaudhary, Nicholas Atwater, Cuong Nguyen, Barry S Brown, John D McNeish, Adam E Cohen, Joel M Kralj. J Pharmacol Toxicol Methods 2016
89
13


Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment.
Valentine J Burroughs, Randall W Maxey, Richard A Levy. J Natl Med Assoc 2002
153
13

How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?
Hg Laverty, C Benson, Ej Cartwright, Mj Cross, C Garland, T Hammond, C Holloway, N McMahon, J Milligan, Bk Park,[...]. Br J Pharmacol 2011
218
13

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
W S Redfern, L Carlsson, A S Davis, W G Lynch, I MacKenzie, S Palethorpe, P K S Siegl, I Strang, A T Sullivan, R Wallis,[...]. Cardiovasc Res 2003
13


Concise review: maturation phases of human pluripotent stem cell-derived cardiomyocytes.
Claire Robertson, David D Tran, Steven C George. Stem Cells 2013
231
13

Assessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans.
V F S Dubois, W E A de Witte, S A G Visser, M Danhof, O Della Pasqua. Pharm Res 2016
17
13

Calcium handling in human induced pluripotent stem cell derived cardiomyocytes.
Ilanit Itzhaki, Sophia Rapoport, Irit Huber, Itzhak Mizrahi, Limor Zwi-Dantsis, Gil Arbel, Jackie Schiller, Lior Gepstein. PLoS One 2011
128
13

Assessment of extracellular field potential and Ca2+ transient signals for early QT/pro-arrhythmia detection using human induced pluripotent stem cell-derived cardiomyocytes.
Najah Abi-Gerges, Amy Pointon, Karen L Oldman, Martin R Brown, Mark A Pilling, Clare E Sefton, Helen Garside, Christopher E Pollard. J Pharmacol Toxicol Methods 2017
27
13

Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells.
Oksana Sirenko, Carole Crittenden, Nick Callamaras, Jayne Hesley, Yen-Wen Chen, Carlos Funes, Ivan Rusyn, Blake Anson, Evan F Cromwell. J Biomol Screen 2013
103
13

Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells.
Xiulan Yang, Marita Rodriguez, Lil Pabon, Karin A Fischer, Hans Reinecke, Michael Regnier, Nathan J Sniadecki, Hannele Ruohola-Baker, Charles E Murry. J Mol Cell Cardiol 2014
260
13

Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testing.
Daniel Sinnecker, Karl-Ludwig Laugwitz, Alessandra Moretti. Pharmacol Ther 2014
63
13

Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes.
Tadahiro Shinozawa, Koki Nakamura, Masanobu Shoji, Maya Morita, Maya Kimura, Hatsue Furukawa, Hiroki Ueda, Masanari Shiramoto, Kyoko Matsuguma, Yoshikazu Kaji,[...]. Stem Cell Reports 2017
34
13

Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes.
Stefan R Braam, Leon Tertoolen, Anja van de Stolpe, Thomas Meyer, Robert Passier, Christine L Mummery. Stem Cell Res 2010
255
13

Structural Immaturity of Human iPSC-Derived Cardiomyocytes: In Silico Investigation of Effects on Function and Disease Modeling.
Jussi T Koivumäki, Nikolay Naumenko, Tomi Tuomainen, Jouni Takalo, Minna Oksanen, Katja A Puttonen, Šárka Lehtonen, Johanna Kuusisto, Markku Laakso, Jari Koistinaho,[...]. Front Physiol 2018
69
13

Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity.
Nicola Ferri, Peter Siegl, Alberto Corsini, Joerg Herrmann, Amir Lerman, Renee Benghozi. Pharmacol Ther 2013
108
13

Assessment of cardiomyocyte contraction in human-induced pluripotent stem cell-derived cardiomyocytes.
Amy Pointon, Alexander R Harmer, Ian L Dale, Najah Abi-Gerges, Joanne Bowes, Christopher Pollard, Helen Garside. Toxicol Sci 2015
65
13

Influence of donor age on induced pluripotent stem cells.
Valentina Lo Sardo, William Ferguson, Galina A Erikson, Eric J Topol, Kristin K Baldwin, Ali Torkamani. Nat Biotechnol 2017
115
13

Patient-specific stem cells and cardiovascular drug discovery.
Nicholas M Mordwinkin, Andrew S Lee, Joseph C Wu. JAMA 2013
27
13

iPS cells: a game changer for future medicine.
Haruhisa Inoue, Naoki Nagata, Hiromi Kurokawa, Shinya Yamanaka. EMBO J 2014
264
13

Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.
Liang Guo, Rory M C Abrams, Joshua E Babiarz, Jennifer D Cohen, Sei Kameoka, Martin J Sanders, Eric Chiao, Kyle L Kolaja. Toxicol Sci 2011
203
13

Current status of drug screening and disease modelling in human pluripotent stem cells.
Divya Rajamohan, Elena Matsa, Spandan Kalra, James Crutchley, Asha Patel, Vinoj George, Chris Denning. Bioessays 2013
73
13

How to improve R&D productivity: the pharmaceutical industry's grand challenge.
Steven M Paul, Daniel S Mytelka, Christopher T Dunwiddie, Charles C Persinger, Bernard H Munos, Stacy R Lindborg, Aaron L Schacht. Nat Rev Drug Discov 2010
13

Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury.
Christopher Goldring, Daniel J Antoine, Frank Bonner, Jonathan Crozier, Chris Denning, Robert J Fontana, Neil A Hanley, David C Hay, Magnus Ingelman-Sundberg, Satu Juhila,[...]. Hepatology 2017
40
13


Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes.
Sara S Nunes, Jason W Miklas, Jie Liu, Roozbeh Aschar-Sobbi, Yun Xiao, Boyang Zhang, Jiahua Jiang, Stéphane Massé, Mark Gagliardi, Anne Hsieh,[...]. Nat Methods 2013
563
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.